TCH GROUP, LLC for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 444, 340B Program Improvement Integrity Act; 340B program issues; H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics; H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness; H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness; H.R. 3590, Patient Protection and Affordable Care Act: comparative effectiveness, 340B program issues, regulatory approval for follow-on biologics, drug labeling, access to clinical trials, importation [S.A. 2793], health reform issues generally; H.R. 3962, Affordable Health Care for America Act: regulatory approval for follow-on biologics, 340B program issues, comparative effectiveness, importation, health reform issues generally; S. 422, The Heart Disease Education, Analysis Research, and Treatment (HEART) for Women Act: new drug application requirements; S. 488, Access to Cancer Clinical Trials Act of 2009: access to clinical trials; S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; S. 914, Cures Acceleration Network and National Institutes of Health Reauthorization of 2009: basic research and development; S. 1142, Informed Health Care Decision Making Act: drug labeling; S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 1679, Affordable Health Choices Act: health reform, regulatory approval pathway for follow-on biologics, 340B program issues, importation; S. 1796, America's Health Future Act of 2009: comparative effectiveness, importation, health reform issues generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Copyright/Patent/Trademark CPT
H.R. 573, To amend the Federal Food , Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions; H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements; H.R. 3590, Patient Protection and Affordable Care Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics, patent settlements, and authorized generics; H.R. 3962, Affordable Health Care for America Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics, and patent settlements; S. 369, Preserve Access to Affordable Generics Act: patent settlements; S. 501, To amend the Federal Food, Drug, and Cosmetics Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions; S. 515, Patent Reform Act of 2009: reforms of the patent laws; S. 610, Patent Reform Act of 2009: reforms of the patent laws: S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; International intellectual property issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Medicare/Medicaid MMM
H.R. 3590, Patient Protection and Affordable Care Act: Part D coverage gap discounts, Part D rebates, Part D issues generally, Medicare payment issues, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform fee and health reform issues generally; H.R. 3962, Affordable Health Care for America Act: Part D coverage gap, Part D rebates, Part D issues generally, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform issues generally; S. 1796, America's Healthy Future Act of 2009: Part D coverage gap discounts, Part D issues generally, Medicare payment issues, Medicaid rebate issues, comparative effectiveness, health reform fee, health reform issues generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Budget/Appropriations BUD
H.R. 2982, Department of Homeland Security Appropriations Act, 2010: importation; H.R. 2997, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010: importation, FDA funding; S. 1298, Department of Homeland Security Appropriations Act, 2010: importation; S. 1406, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010: importation, FDA funding; H.R. 3288, Consolidated Appropriations Act: comparative effectiveness, NIH funding, pandemic funding
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.